I Ask This Of You!
I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.
I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.
This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns.
Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.
This is a free site for all with no advertisements.
Thank you for visiting!
Friday, May 3, 2013
Head trauma has long been implicated as one of the causes of Parkinson's Disease. Researchers recently assessed people with Parkinson's Disease who had head trauma so serious that it had led to concussion. They conducted a sensitivity analysis to assess the influence of each study. After reviewing more than 636 article titles, 34 articles were selected for full review. In total, 22 studies were included in the assessment.
Rajesh Pahwa (Editor), Kelly E. Lyons (Editor)
THE PARKINSON HUB
ISTRADEFYLLINE CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Researchers evaluated the efficacy and safety of istradefylline, which is being developed for the treatment of Parkinson's Disease. Istradefylline is an A(2A) adenosine receptor antagonist and so does not act by directly increasing the activity of dopamine. It is administered with L-dopa.
Researchers assessed the safety, tolerability and efficacy of a new form of apomorphine presently being developed, called VR040, which is an inhaled dry powder. Apomorphine is a dopamine agonist used in the treatment of Parkinson's Disease. 'Off' periods usually increase as Parkinson's Disease progresses and the benefits of standard therapy wane. Subcutaneous (injected) apomorphine rescues 'off' periods, but injections by patients and adverse effects are sometimes problematic.
PARKINSON'S TREATMENT : 10 SECRETS TO A HAPPIER LIFE
Michael S.Okun MD
HOW TO LIVE WELL WITH PARKINSON'S : ADVICE FROM A PHYSICAL THERAPIST
Miriam P. Boelen